SG176062A1 - Compositions and methods for treating ischemia and ischemia-reperfusion injury - Google Patents
Compositions and methods for treating ischemia and ischemia-reperfusion injury Download PDFInfo
- Publication number
- SG176062A1 SG176062A1 SG2011083862A SG2011083862A SG176062A1 SG 176062 A1 SG176062 A1 SG 176062A1 SG 2011083862 A SG2011083862 A SG 2011083862A SG 2011083862 A SG2011083862 A SG 2011083862A SG 176062 A1 SG176062 A1 SG 176062A1
- Authority
- SG
- Singapore
- Prior art keywords
- ischemia
- injury
- compound
- reperfusion injury
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 52
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract 47
- 208000028867 ischemia Diseases 0.000 title claims abstract 28
- 208000012947 ischemia reperfusion injury Diseases 0.000 title claims abstract 25
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 150000001875 compounds Chemical class 0.000 claims abstract 36
- 208000027418 Wounds and injury Diseases 0.000 claims 18
- 230000006378 damage Effects 0.000 claims 18
- 208000014674 injury Diseases 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 12
- 208000037906 ischaemic injury Diseases 0.000 claims 9
- 201000006474 Brain Ischemia Diseases 0.000 claims 8
- 238000001356 surgical procedure Methods 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 6
- -1 nitro, cyano, cyclopropyl Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 4
- 208000004535 Mesenteric Ischemia Diseases 0.000 claims 4
- 206010063897 Renal ischaemia Diseases 0.000 claims 4
- 210000003489 abdominal muscle Anatomy 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 206010009887 colitis Diseases 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 201000002818 limb ischemia Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000003683 cardiac damage Effects 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/466,170 US7928067B2 (en) | 2009-05-14 | 2009-05-14 | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| PCT/US2010/034701 WO2010132657A1 (en) | 2009-05-14 | 2010-05-13 | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG176062A1 true SG176062A1 (en) | 2011-12-29 |
Family
ID=42244916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011083862A SG176062A1 (en) | 2009-05-14 | 2010-05-13 | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7928067B2 (enExample) |
| EP (1) | EP2429519B1 (enExample) |
| JP (2) | JP5570590B2 (enExample) |
| KR (1) | KR101636395B1 (enExample) |
| CN (1) | CN102802622B (enExample) |
| AU (1) | AU2010249001B2 (enExample) |
| BR (1) | BRPI1012182A2 (enExample) |
| CA (1) | CA2761798C (enExample) |
| DK (1) | DK2429519T3 (enExample) |
| ES (1) | ES2470673T3 (enExample) |
| IL (2) | IL216349A (enExample) |
| MX (2) | MX2011012095A (enExample) |
| NZ (1) | NZ596364A (enExample) |
| PL (1) | PL2429519T3 (enExample) |
| SG (1) | SG176062A1 (enExample) |
| WO (1) | WO2010132657A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| WO2012067947A1 (en) | 2010-11-18 | 2012-05-24 | Ischemix Llc | Lipoyl compounds and their use for treating ischemic injury |
| EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| KR101873773B1 (ko) | 2012-05-11 | 2018-08-02 | 주식회사 젬백스앤카엘 | 류마티즘 관절염 예방 또는 치료 조성물 |
| KR20210025132A (ko) | 2012-05-11 | 2021-03-08 | 주식회사 젬백스앤카엘 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
| WO2014010971A1 (ko) | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| KR102258864B1 (ko) | 2013-04-19 | 2021-06-01 | 주식회사 젬백스앤카엘 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| CA2926183C (en) | 2013-10-23 | 2018-07-03 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| JP6553605B2 (ja) | 2013-11-22 | 2019-07-31 | ジェムバックス アンド カエル カンパニー，リミティド | 血管新生抑制活性を有するペプチド、及びそれを含む組成物 |
| ES2809251T3 (es) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composición para tratar cáncer de próstata |
| WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
| WO2015174948A1 (en) | 2014-05-14 | 2015-11-19 | Ischemix, LLC | Formulations comprising lipoyl compounds |
| CN104095835A (zh) * | 2014-06-20 | 2014-10-15 | 广州军区广州总医院 | 对羟基苄叉丙酮在制备预防和/或治疗肝缺血/再灌注损伤药物中的应用 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| ES2799511T3 (es) | 2015-02-27 | 2020-12-18 | Gemvax & Kael Co Ltd | Péptido para prevenir la pérdida de audición, y composición que lo comprende |
| EP3318265B1 (en) | 2015-07-02 | 2021-08-18 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| KR20180123512A (ko) | 2016-04-07 | 2018-11-16 | 주식회사 젬백스앤카엘 | 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN106083800A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用 |
| KR20190062502A (ko) * | 2016-10-05 | 2019-06-05 | 미토브리지, 인크. | 급성 신장 손상을 치료하는 방법 |
| EP4282411A1 (en) * | 2017-04-25 | 2023-11-29 | Ischemix LLC | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury |
| KR102139678B1 (ko) | 2017-11-24 | 2020-07-31 | 전북대학교 산학협력단 | N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물 |
| KR102112949B1 (ko) | 2019-02-12 | 2020-05-19 | 남현규 | 복합 효모 발효로 불용 단백질을 가용화하여 화장품원료를 추출하는 화장품원료 제조방법 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1047991B (de) | 1957-11-20 | 1958-12-31 | Nordmark Werke Gmbh | Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure |
| US3875207A (en) * | 1967-01-25 | 1975-04-01 | Ciba Geigy Corp | Process for the temporary protection of amino groups in peptide syntheses |
| CA1219824A (en) | 1981-04-17 | 1987-03-31 | David C. Ward | Modified nucleotides and methods of preparing and using same |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| FR2653334B1 (fr) | 1989-10-19 | 1991-12-20 | Erphar Ste Civile | Preparation cosmetique de bronzage. |
| DK0427247T3 (da) | 1989-11-09 | 1998-09-28 | Asta Medica Ag | Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel |
| DE4000397A1 (de) | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
| US5556710A (en) | 1992-04-24 | 1996-09-17 | Biocompatibles Limited | Metal coating useful for rendering the surface of the metal biocompatible |
| DE4235912C2 (de) | 1992-10-23 | 2002-12-05 | Viatris Gmbh | Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung |
| DE4433764A1 (de) | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| WO1997000889A1 (en) * | 1995-06-21 | 1997-01-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Peptides binding to low-density lipoproteins |
| JPH0990542A (ja) | 1995-09-28 | 1997-04-04 | Konica Corp | ハロゲン化銀写真感光材料 |
| FR2741075B1 (fr) | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant |
| AU728488B2 (en) | 1997-04-02 | 2001-01-11 | Sankyo Company Limited | Dithiolan derivatives, their preparation and their therapeutic effect |
| JPH117099A (ja) | 1997-06-13 | 1999-01-12 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| US6090842A (en) | 1998-03-10 | 2000-07-18 | The Regents Of The University Of California | Lipoic acid analogs |
| DE19834608A1 (de) | 1998-07-31 | 2000-02-03 | Basf Ag | Kristallmodifikation der Liponsäure |
| JP2000169371A (ja) | 1998-10-02 | 2000-06-20 | Sankyo Co Ltd | ジチオラン誘導体を含有する医薬 |
| AU758903B2 (en) | 1998-11-26 | 2003-04-03 | Pentapharm Ag | Transport system conjugate |
| WO2001009118A2 (en) | 1999-07-29 | 2001-02-08 | Patrick T Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| EP2368898B1 (en) * | 1999-11-18 | 2014-10-01 | Ischemix, Inc | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| JP2002189271A (ja) | 2000-12-21 | 2002-07-05 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその処理方法 |
| DE60234164D1 (de) | 2001-03-19 | 2009-12-10 | Senju Pharma Co | Neues a-liponsäurederivat und dessen verwendung |
| WO2002096360A2 (en) | 2001-05-25 | 2002-12-05 | Ceremedix, Inc. | Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| JP4259813B2 (ja) | 2001-05-29 | 2009-04-30 | 千寿製薬株式会社 | α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤 |
| DE10163836A1 (de) | 2001-12-22 | 2003-07-10 | Friz Biochem Gmbh | Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren |
| WO2003055853A1 (en) | 2001-12-26 | 2003-07-10 | Nippon Soda Co., Ltd. | Electron-accepting compounds capable of forming self-assembled monolayers |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| WO2003072052A2 (en) | 2002-02-22 | 2003-09-04 | Albany College Of Pharmacy | Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease |
| JP2003286168A (ja) | 2002-03-28 | 2003-10-07 | Senju Pharmaceut Co Ltd | α−リポイルアミノ酸を含有する皮膚外用剤 |
| JP4376540B2 (ja) | 2002-05-31 | 2009-12-02 | アイバイツ株式会社 | 金属表面修飾剤および新規含硫黄化合物 |
| US7030154B2 (en) | 2002-06-07 | 2006-04-18 | Juvenon, Inc. | Stability of lipoic acid |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| US20040204340A1 (en) * | 2003-04-11 | 2004-10-14 | Guilford Pharmaceuticals, Inc. | Polyprolyl inhibitors of cyclophilin |
| US7202270B2 (en) | 2003-06-20 | 2007-04-10 | Sami Labs Limited | Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses |
| WO2005063732A1 (en) | 2003-12-23 | 2005-07-14 | Microbia, Inc. | Compounds and methods for the treatment of asthma |
| KR100811969B1 (ko) | 2004-02-18 | 2008-03-10 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | 당쇄 리간드 복합체, 및 그 리간드 복합체를 이용한단백질의 분석 방법 |
| JP2006022066A (ja) | 2004-07-09 | 2006-01-26 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| WO2006101910A2 (en) | 2005-03-16 | 2006-09-28 | Ischemix, Inc. | Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems |
| WO2006101909A2 (en) | 2005-03-16 | 2006-09-28 | Ischemix, Inc. | Combination therapy for treating or preventing diseases |
| JP2008174453A (ja) | 2005-04-28 | 2008-07-31 | Iwaki Kk | 頭皮脱毛治療剤 |
| US8507439B2 (en) | 2005-08-29 | 2013-08-13 | Angela Shashoua | Neuroprotective and neurorestorative method and compositions |
| JP4951226B2 (ja) | 2005-09-08 | 2012-06-13 | 立山化成株式会社 | α−リポ酸アルカリ塩の製法 |
| WO2007030581A2 (en) * | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| ATE464890T1 (de) | 2006-03-28 | 2010-05-15 | Epitech Group Srl | Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden |
| JP2012508165A (ja) | 2008-11-07 | 2012-04-05 | イスティテュート ビオキーミコ ナッツィオナーレ サーヴィオ エスアールエル | α−リポ酸誘導体及び薬物製剤へのそれらの使用 |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| US8080674B2 (en) | 2009-06-12 | 2011-12-20 | Ampac Fine Chemicals Llc. | Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt |
| US8410162B2 (en) | 2009-06-15 | 2013-04-02 | Encore Health Llc | Choline esters |
| EP3542629A3 (en) | 2009-06-15 | 2020-01-01 | Encore Health, LLC | Dithiol compounds, derivatives, and uses therefor |
| IT1397154B1 (it) | 2010-01-04 | 2013-01-04 | Ghelardini | Composti ad efficacia sia analgesica che antiperalgesica. |
| WO2012067947A1 (en) | 2010-11-18 | 2012-05-24 | Ischemix Llc | Lipoyl compounds and their use for treating ischemic injury |
| US20150329519A1 (en) | 2014-05-14 | 2015-11-19 | Ischemix, LLC | Formulations Comprising Lipoyl Compounds |
| WO2015174948A1 (en) | 2014-05-14 | 2015-11-19 | Ischemix, LLC | Formulations comprising lipoyl compounds |
-
2009
- 2009-05-14 US US12/466,170 patent/US7928067B2/en active Active
-
2010
- 2010-05-13 NZ NZ596364A patent/NZ596364A/xx not_active IP Right Cessation
- 2010-05-13 MX MX2011012095A patent/MX2011012095A/es active IP Right Grant
- 2010-05-13 DK DK10720092.5T patent/DK2429519T3/da active
- 2010-05-13 ES ES10720092.5T patent/ES2470673T3/es active Active
- 2010-05-13 CA CA2761798A patent/CA2761798C/en active Active
- 2010-05-13 BR BRPI1012182A patent/BRPI1012182A2/pt not_active Application Discontinuation
- 2010-05-13 JP JP2012511009A patent/JP5570590B2/ja active Active
- 2010-05-13 MX MX2013004034A patent/MX347460B/es unknown
- 2010-05-13 KR KR1020117029417A patent/KR101636395B1/ko active Active
- 2010-05-13 PL PL10720092T patent/PL2429519T3/pl unknown
- 2010-05-13 EP EP10720092.5A patent/EP2429519B1/en active Active
- 2010-05-13 SG SG2011083862A patent/SG176062A1/en unknown
- 2010-05-13 CN CN201080031479.5A patent/CN102802622B/zh active Active
- 2010-05-13 AU AU2010249001A patent/AU2010249001B2/en not_active Ceased
- 2010-05-13 US US13/319,839 patent/US8772250B2/en active Active
- 2010-05-13 WO PCT/US2010/034701 patent/WO2010132657A1/en not_active Ceased
-
2011
- 2011-03-04 US US13/041,001 patent/US8772249B2/en active Active
- 2011-11-14 IL IL216349A patent/IL216349A/en active IP Right Grant
-
2013
- 2013-12-12 JP JP2013257143A patent/JP5767307B2/ja active Active
-
2014
- 2014-05-21 US US14/283,844 patent/US20140274917A1/en not_active Abandoned
-
2015
- 2015-03-19 IL IL237820A patent/IL237820A/en active IP Right Grant
- 2015-10-20 US US14/918,175 patent/US9540417B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010249001B2 (en) | Compositions and methods for treating ischemia and ischemia-reperfusion injury | |
| AU2011329215C1 (en) | Lipoyl compounds and their use for treating ischemic injury | |
| HK1167082B (en) | Compositions and methods for treating ischemia and ischemia-reperfusion injury | |
| HK1189803B (en) | Lipoyl compounds and their use for treating ischemic injury | |
| HK1189803A (en) | Lipoyl compounds and their use for treating ischemic injury | |
| KR20050006130A (ko) | 환식 반아세탈 유도체 및 이의 용도 |